Bartter syndrome medical therapy
Main article: Bartter syndrome
|
Bartter syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bartter syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Bartter syndrome medical therapy |
|
Risk calculators and risk factors for Bartter syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]
Overview
Medical Therapy
- Prostaglandin synthetase inhibitors suppress the production of prostaglandin. This corrects all the chemical features of the syndrome except the urinary loss of potassium.[1]
- Hypokalemia should be treated. Potassium chloride supplements are preferred salt because of the coexisting chloride deficiencies in these patients.
- Spironolactone, aldosterone antagonist.
- Amiloride reduces potassium and hydrogen excretion, by inhibiting epithelial sodium channels (ENaC).
- Triamterene decreases calcium excretion and increases magnesium loss.
- Angiotensin-converting enzyme (ACE) inhibitors, such as captopril, enalapril and lisinopril.
- Nonsteroidal drug anti-inflammatory drugs (NSAID) such as indomethacin and naproxen which decrease the activity of the enzyme cyclo-oxygenase (COX) which increases prostaglandin synthesis.
- Growth hormone (GH) for growth retardation.
- Calcium or magnesium supplements in the presence of muscle spasm and tetany.[2]
References
- ↑ Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW; et al. (1976). "Bartter's syndrome: a disorder characterized by high urinary prostaglandins and dependence of hyperreninemia on prostaglandin synthesis". Am J Med. 61 (1): 43–51. doi:10.1016/0002-9343(76)90029-2. PMID 820194.
- ↑ Al Shibli A, Narchi H (2015). "Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations". World J Methodol. 5 (2): 55–61. doi:10.5662/wjm.v5.i2.55. PMC 4482822. PMID 26140272.